These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21115578)

  • 41. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
    Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
    Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low alpha-fetoprotein hepatocellular carcinoma.
    Carr BI; Pancoska P; Branch RA
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1543-9. PubMed ID: 20796153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The diagnostic approach to hepatocellular carcinoma].
    Schacherer D; Schoelmerich J; Zuber-Jerger I
    Z Gastroenterol; 2007 Oct; 45(10):1067-74. PubMed ID: 17924305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advancements in hepatocellular carcinoma.
    Kulik LM
    Curr Opin Gastroenterol; 2007 May; 23(3):268-74. PubMed ID: 17414842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Staging classifications for hepatocellular carcinoma.
    Van Deusen MA; Abdalla EK; Vauthey JN; Roh MS
    Expert Rev Mol Diagn; 2005 May; 5(3):377-83. PubMed ID: 15934814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
    Tateishi R; Shiina S; Yoshida H; Teratani T; Obi S; Yamashiki N; Yoshida H; Akamatsu M; Kawabe T; Omata M
    Hepatology; 2006 Dec; 44(6):1518-27. PubMed ID: 17133456
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand.
    Tangkijvanich P; Tosukhowong P; Bunyongyod P; Lertmaharit S; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 1999 Mar; 30(1):110-4. PubMed ID: 10695798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Measurement of alpha-fetoprotein with L3 fraction in the early diagnosis of patients with hepatocellular carcinoma].
    Aoyagi Y; Kubota T
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():625-8. PubMed ID: 16149595
    [No Abstract]   [Full Text] [Related]  

  • 49. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.
    Soresi M; Magliarisi C; Campagna P; Leto G; Bonfissuto G; Riili A; Carroccio A; Sesti R; Tripi S; Montalto G
    Anticancer Res; 2003; 23(2C):1747-53. PubMed ID: 12820452
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Staging of hepatocellular carcinoma.
    Yan P; Yan LN
    Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):491-5. PubMed ID: 14627506
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients.
    Tateishi R; Yoshida H; Shiina S; Imamura H; Hasegawa K; Teratani T; Obi S; Sato S; Koike Y; Fujishima T; Makuuchi M; Omata M
    Gut; 2005 Mar; 54(3):419-25. PubMed ID: 15710994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatocellular carcinoma.
    Marrero JA; Pelletier S
    Clin Liver Dis; 2006 May; 10(2):339-51, ix. PubMed ID: 16971265
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multidisciplinary management of hepatocellular carcinoma: where are we today?
    Marrero JA
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S3-10. PubMed ID: 23457037
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Markers for hepatocellular carcinoma.
    Wu AH; Sell S
    Immunol Ser; 1990; 53():403-22. PubMed ID: 1713067
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Staging systems for hepatocellular carcinoma: should we all use the BCLC system?
    Marrero JA
    J Hepatol; 2006 Apr; 44(4):630-2. PubMed ID: 16503077
    [No Abstract]   [Full Text] [Related]  

  • 57. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?
    Farinati F; Marino D; De Giorgio M; Baldan A; Cantarini M; Cursaro C; Rapaccini G; Del Poggio P; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Bernardi M; Trevisani F
    Am J Gastroenterol; 2006 Mar; 101(3):524-32. PubMed ID: 16542289
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort.
    Marrero JA; Fontana RJ; Barrat A; Askari F; Conjeevaram HS; Su GL; Lok AS
    Hepatology; 2005 Apr; 41(4):707-16. PubMed ID: 15795889
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response.
    Guglielmi A; Ruzzenente A; Pachera S; Valdegamberi A; Sandri M; D'Onofrio M; Iacono C
    Am J Gastroenterol; 2008 Mar; 103(3):597-604. PubMed ID: 17970836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of staging systems to predict survival in hepatocellular carcinoma.
    Pascual S; Zapater P; Such J; García-Herola A; Sempere L; Irurzun J; Palazón JM; Carnicer F; Pérez-Mateo M
    Liver Int; 2006 Aug; 26(6):673-9. PubMed ID: 16842323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.